## barchart

## **SANOFI**

### FORM 6-K

(Report Of Foreign Issuer)

### Filed 07/05/23 for the Period Ending 07/05/23

Address 54 RUE LA BOETIE, PARIS, I0, 75008

Telephone (727) 384-2323

CIK 0001121404

Symbol SNY

SIC Code 2834 - Pharmaceutical Preparations

Fiscal Year 12/31

#### Powered by **barchart**

https://www.barchart.com/solutions
© Copyright 2022, Barchart.com, Inc. All Rights Reserved.

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| FORM 6-K  |
|---|
| REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934                |
| For the month of July 2023  |
| Commission File Number: 001-31368   |
| SANOFI (Translation of registrant's name into English)  |
| 46, avenue de la Grande Armée, 75017 Paris, FRANCE (Address of principal executive offices)                                 |
| Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.         |
| Form 20-F ⊠ Form 40-F □   |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): |

In June 2023, Sanofi published the press releases attached hereto as Exhibits 99.1, 99.2 and 99.3 which are incorporated herein by reference.

#### **Exhibit Index**

| Exhibit No.  | <u>Description</u>   |
|--------------|--|
| Exhibit 99.1 | Press Release dated June 25, 2023: FDA ALTUVIIIOä late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing                     |
| Exhibit 99.2 | Press Release dated June 27, 2023: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody |
| Exhibit 99.3 | Press Release dated June 29, 2023: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease  |

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 5, 2023 SANOFI

By <u>/s/ Alexandra Roger</u>
Name: Alexandra Roger
Title: Head of Securities Law and Capital Markets